Blog

26 Feb Real World Data in the Regulatory & Reimbursement process – Implications for value and access

Posted at 18:36h in Blog

From mobile devices to wearables and biosensors, digital innovation has led to an exponential increase in the availability of health-related data. While the healthcare market has traditionally been slow to adopt digital innovations (in 2017 14% of US clinician offices still relied on paper medical records) there are now a multitude of ways healthcare companies...

18 Feb Implications of Pharmaceutical Price Transparency in Television Advertising

Posted at 19:24h in Blog

In May of 2018, the Trump administration released a proposal which it described as a blueprint to address rising pharmaceutical costs. The proposal, American Patients First, consisted of four key strategies for reform (you can read the full Jupiter assessment here) including an effort to...

11 Feb The impact of legislative and public scrutiny on pharmaceutical price increases

Posted at 16:10h in Blog

In many respects, 2018 appeared as though Donald Trump might make good on his key campaign promise to curb increasing pharmaceutical prices. With public and legislative scrutiny of manufacturer pricing practices continually increasing, the Trump White House released their “blueprint” for addressing rising drug costs,...

04 Feb The increasing role of state legislature in pharmaceutical pricing and access

Posted at 15:59h in Blog

As public and political scrutiny of drug prices continues, pharmaceutical companies are increasingly encountering new governmental efforts to control rising drug costs. At the federal level, this scrutiny resulted in the publication of the Trump administration’s American Patients First blueprint last year. While the major...

21 Jan Jupiter Life Sciences Consulting Announces Saleem J Shah as Partner

Posted at 14:30h in News

LONDON – Jan. 21, 2019 Jupiter Life Sciences Consulting, a global leader in market access and pricing strategy in the biopharmaceutical industry, are delighted to announce the appointment of Saleem J Shah (Sal) as Partner. Based in London, Sal will build and lead European...

25 May Trump’s drug pricing plan: light on details, heavy on questions

Posted at 15:00h in Blog

With the recent publication of American Patients First, the Trump administration has provided what it describes as a “blueprint to lower drug prices and reduce patient out-of-pocket costs.” Less a blueprint than a general position document, American Patients First is light on details and heavy...

27 Mar A Roadmap to Optimizing Price in the Pharmaceutical Industry

Posted at 11:41h in Blog

Determining the right price for a drug involves analyzing multiple variables and carefully articulating value to stakeholders. Here’s a big-picture view of the process. Pricing pharmaceuticals is not only complex, involving multiple variables and affecting numerous stakeholders, it’s also intensely politically sensitive. Increasing scrutiny of the...

07 Mar Biotech Innovators: Plan Globally, Act Locally

Posted at 10:41h in Blog

Jupiter helps biotech innovators build custom optimal market access and pricing solutions tailored to local market dynamics and payer requirements As we continue to expand our presence globally, the breadth of Jupiter’s experience with companies throughout the world uniquely qualifies us to help biotech innovators...

13 Feb Jupiter Life Science Consulting Launches New Subscription-Based Market Research Solution for Pharma and Biotech Industries

Posted at 17:26h in News

BOSTON – Feb. 13, 2018 – Jupiter Life Science Consulting, a global leader in market access and pricing strategy in the biopharmaceutical industry, today announced the launch of its payer engagement solution, Quick Qual (Q2). Jupiter’s new payer intelligence service ensures pharma and biotech innovators...

12 Dec Jupiter Life Science Consulting Acquires Alta Bioscience Consulting

Posted at 22:05h in News

BOSTON – Dec. 12, 2017 – Jupiter Life Science Consulting, a global leader in market access and pricing strategy in the biopharmaceutical industry, today announced the acquisition of Alta Bioscience Consulting. Alta is a global provider of advisory services in the development and commercialization of...